Cardiac Sarcoidosis: A Patient's Guide to the Heart Disease That Hides as Heart Block, Bad Rhythms, or Heart Failure

Patients caught early do much better than patients whose diagnosis gets missed for years, and this one is a chameleon. It can look like an electrical problem, a rhythm problem, or a pumping problem, and it can hit the heart without showing up anywhere else in the body.

What sarcoidosis is, and how it gets into the heart

Sarcoidosis is a multi-system inflammatory disease of the immune system itself, not one organ. Immune cells that should be fighting infection clump together in tissue instead, forming granulomas, tiny under a microscope and still enough to jam how an organ works. Nobody knows what sets it off, and it can stay quiet for years, flare, settle, and flare again. About 90 percent of sarcoidosis patients have lung involvement, usually swollen chest lymph nodes and some lung scarring. Eyes come next, then skin, lymph nodes elsewhere, liver, and nervous system.

About 5 to 10 percent of sarcoidosis patients have noticeable heart symptoms in their lifetime, and autopsy studies find heart involvement in 20 to 30 percent. A lot of cardiac sarcoidosis is silent until it isn’t. Roughly a quarter of cases are isolated cardiac sarcoidosis, meaning no lung disease, no skin findings, no eye involvement, just the heart, and those are the hardest to diagnose because there’s no extra-cardiac clue to anchor the workup.

Granulomas disrupt whatever they touch. On the electrical wiring, a conduction problem. In the muscle, dangerous rhythms. Spread widely, the heart can’t pump. They have a favorite spot, the upper part of the wall between the two pumping chambers, called the basal interventricular septum. The AV node and the bundle of His run right through there, which is why heart block is such a classic presentation.

Most patients are between 30 and 60. Sarcoidosis runs about three times higher in Black/African American populations than in white populations in the US, and it’s common in Scandinavian populations. It clusters in families without a clean inheritance pattern. Anyone diagnosed with sarcoidosis in the lungs, eyes, or skin should be screened for heart involvement.

The three ways it shows up

Heart block comes first. Your heart’s signal starts in the SA node, travels to the AV node, then through the bundle of His into the bundle branches. First-degree block means the signal takes longer than it should. Second-degree means some signals don’t get through. Third-degree, or complete heart block, means none do and the bottom of the heart falls back on its own slower, less reliable pacing. Granulomas piling up in the basal septum physically interrupt that signal. Caught in the inflammatory phase, conduction sometimes recovers with treatment. Once the granulomas turn to scar, the block is usually permanent and needs a pacemaker.

The classic patient: a 42-year-old with no heart history comes to the emergency room lightheaded after climbing stairs at work. His electrocardiogram (EKG) shows complete heart block, his coronary arteries look clean on CT, and his echocardiogram shows a slightly thinned upper septum with mildly reduced pumping. Never smoked, no family history. He gets a temporary external pacemaker, and the question that has to follow is why a 42-year-old without coronary disease has complete heart block. Asking it before a permanent pacemaker goes in changes the plan, because the answer decides which device he needs and starts the treatment that keeps this from progressing.

Ventricular tachycardia is the second pattern. VT is a fast rhythm from the bottom chambers, often 150 to 250 beats per minute, that doesn’t pump blood well. Short runs feel like palpitations or fluttering. Sustained VT causes lightheadedness, fainting, chest pain, or cardiac arrest. The boundary between healthy muscle and sarcoid scar is a perfect setup for a re-entrant rhythm, where the signal gets stuck in a loop. Cardiac sarcoidosis is a textbook cause of VT in hearts that look fairly normal on the first ultrasound, and it turns up in 3 to 10 percent of younger patients with unexplained sudden cardiac death. Someone who survives an arrest needs the inflammation calmed down and protection from the next one with an implantable defibrillator.

The third pattern is a weakened, dilated heart. Granulomas spread through the wall and the ejection fraction, the percentage of blood pumped out with each beat, falls. Patients notice breathlessness on stairs, swollen feet and ankles, extra pillows at night, and a drop in exercise tolerance. Those symptoms belong to every cause of heart failure, which is how this gets mislabeled as idiopathic non-ischemic cardiomyopathy. The tell is in the imaging. Wall thinning is patchy and uneven, often in the upper septum, and on cardiac MRI the scar doesn’t match any single coronary artery’s territory. Late-stage disease thins the wall enough that small aneurysms form along the bottom or side of the heart, and those areas go electrically unstable too.

How we diagnose it

No single blood test confirms cardiac sarcoidosis. The diagnosis comes from the clinical pattern, an echocardiogram, a cardiac MRI, a PET scan, and a search for sarcoidosis elsewhere. The Heart Rhythm Society published structured criteria in 2014 laying out two paths. The first is finding granulomas directly on a heart muscle biopsy, rarely used because granulomas are patchy and a small sample misses them. The second, the one most patients are diagnosed through, is finding granulomas elsewhere in the body and pairing that with the right cardiac findings, meaning heart block, ventricular arrhythmia, a scar pattern on MRI, active inflammation on PET, or an unexplained drop in ejection fraction.

In clinic I ask about more than the symptom that brought you in. Any unexplained cough or shortness of breath. Any rashes, especially raised purple or red bumps on the shins, called erythema nodosum. Any eye redness or vision change called uveitis. Any swollen lymph nodes in the neck or armpits. Any family history of sarcoidosis. I ask about ancestry too. None of it confirms anything, and all of it shifts my suspicion before I order a test.

The echocardiogram is an ultrasound of the heart, 30 to 45 minutes, no radiation. I’m looking for thinning of the upper septum, wall motion problems that don’t match a coronary territory, a reduced ejection fraction, and aneurysm-like bulges. Strain imaging, which measures how far each part of the muscle stretches per beat, sometimes catches what the basic picture misses.

The cardiac MRI uses a strong magnet rather than radiation. You lie in a tube for 45 minutes to an hour, holding your breath 10 to 20 seconds at a time during the important images, and a contrast dye called gadolinium goes in through a small IV halfway through. The useful part is late gadolinium enhancement. Dye washes out of healthy muscle quickly and lingers in scar, so pictures taken 10 to 20 minutes after the injection light up scarred areas against dark normal muscle. In sarcoidosis that scar is patchy and sits in the middle or outer part of the wall, especially the upper septum. Heart attack scar follows one coronary artery’s territory and runs through the wall from the inside. Amyloid scar is more uniform and just under the surface. The MRI also measures pumping strength and chamber size precisely and spots active swelling as opposed to old burnt-out scar. The 2013 Greulich study in JACC: Cardiovascular Imaging showed that late gadolinium enhancement predicts future bad events in suspected cardiac sarcoidosis.

We also go looking elsewhere, because granulomas anywhere strengthen the diagnosis without a heart biopsy. That means a chest CT for swollen chest lymph nodes and patchy lung scarring, a slit-lamp eye exam by an ophthalmologist for silent uveitis, a dermatologist for skin findings such as lupus pernio or scar-like facial lesions, and a check for lymph nodes you can feel in the neck, armpits, or groin, which are easy to biopsy. Sometimes a whole-body PET when nothing else turns up. A chest lymph node sampled through an EBUS procedure, a bronchoscope with an ultrasound probe, is usually cleaner than going after the heart. When it’s all still uncertain we do an endomyocardial biopsy, taking tiny pieces of muscle through a vein with a catheter into the right side of the heart. The yield is modest and improves when the biopsy is aimed where the PET or MRI shows the worst involvement.

The PET scan, and why the diet is not optional

The PET scan tells us whether inflammation is active right now or burnt out, and that drives treatment, because steroids work on active inflammation and do nothing for old scar.

Cardiac PET uses radioactive sugar, called FDG, as its tracer. Inflammatory cells take up sugar and light up, and so does healthy heart muscle, so if your heart is eating sugar during the scan the whole thing lights up and we see nothing useful. The fix is a 24-hour high-fat, low-carbohydrate, no-sugar diet that shifts your heart onto fat. Normal muscle goes dark and inflamed patches still glow.

The day before, eat eggs cooked in butter, bacon, avocado, cheese, plain nuts such as walnuts, almonds, or macadamia, cottage cheese, unsweetened Greek yogurt, olive oil, and salads with full-fat dressing. Avoid bread, rice, pasta, tortillas, fruit and fruit juice, sweets, desserts, soda, beer and most alcohol, beans and starchy vegetables, and milk, though some imaging centers allow a small amount. After dinner you fast for 12 to 18 hours, water and black coffee allowed. Follow it loosely and the scan comes back uninterpretable, which wastes your time and money and means doing it again. I’m strict about this.

On scan day they check your blood sugar, inject the tracer through an IV, and let you rest 30 to 60 minutes while it distributes. The scan runs about 30 minutes on a table that moves through a donut-shaped scanner, and there’s no contrast injection. The tracer wears off the same day and you can drive yourself home and eat normally. You’ll be slightly radioactive for about 24 hours, so avoid prolonged close contact with pregnant women and small children.

Treatment, in three layers

The first layer calms the inflammation. Prednisone is the steroid I use, starting at 30 to 40 milligrams a day, occasionally up to 60 milligrams in severe presentations. High-dose steroids over long stretches do real damage, so I use the lowest dose that works. Once a repeat PET shows the inflammation is quiet, usually a few months in, we taper over 6 to 12 months, typically 40 milligrams for a month, then 30, then 20, then slower steps through 10, 7.5, 5, and off if you stay in remission.

Expect increased appetite and some weight gain, sometimes a “moon face” from fluid in the cheeks, and mood changes that can go either direction. Take it in the morning, because a late dose wrecks sleep. I monitor your blood sugar and blood pressure more often on prednisone, since both can climb and prediabetes can tip into diabetes on high doses. Longer term, steroids thin bone, so I add calcium and vitamin D and, past three months of treatment, usually a bisphosphonate such as alendronate. They speed cataract formation, so get a yearly eye exam. They dial down your immune system, which makes flu, COVID, shingles, and pneumonia vaccines more valuable, not less. I add a stomach-protective drug such as omeprazole if you have an ulcer history or take aspirin or a blood thinner. Your own adrenal steroid production goes sleepy after several months, which is why we taper slowly instead of stopping cold.

If you can’t tolerate long steroid courses, relapse during the taper, or have severe disease, we add a steroid-sparing drug so we can use less prednisone. Methotrexate is the usual choice, with azathioprine and mycophenolate as alternatives. In refractory cases a biologic like infliximab, a TNF blocker, can be used, though the evidence in cardiac sarcoidosis is thinner than in the diseases it was built for. I make those decisions with a rheumatologist or pulmonologist who handles sarcoidosis daily.

The second layer protects you from dangerous rhythms. A pacemaker is a small device under the skin near your collarbone, with one or two wires into the heart through a vein, providing a backup beat when the natural signal is too slow or doesn’t conduct. Indications match other causes of block, meaning complete heart block, advanced second-degree block, or significant symptomatic pauses. The wrinkle is that sarcoidosis carries arrhythmia risk beyond the conduction problem, because the granulomas jamming the wiring usually have company out in the muscle. An implantable cardioverter-defibrillator (ICD) looks similar and does more, watching for dangerous fast rhythms and shocking the heart back to normal. The shock feels like a hard punch to the chest and it saves lives. The 2014 Heart Rhythm Society guidelines recommend that a cardiac sarcoidosis patient needing pacing for heart block get a device that can also defibrillate, an ICD or a CRT-D, rather than a plain pacemaker, with the exact choice depending on ejection fraction, MRI findings, and electrophysiology study results. Cardiac resynchronization therapy (CRT), a three-wire device that gets the bottom chambers contracting in sync, helps when pumping is weak and the QRS on the EKG is wide.

When VT keeps happening despite the device, we add antiarrhythmic medication. Amiodarone is the most commonly used because it works when others don’t, and it carries a long list of side effects involving the thyroid, lung, liver, eye, and skin that I have to monitor. Sotalol is an option in selected patients. Catheter ablation, where an electrophysiologist threads catheters in and burns the unstable patches, helps when medication isn’t enough. It’s harder here than in most conditions because the disease is patchy and progressive, and in experienced hands it still cuts the number of shocks.

The third layer supports the pumping. A reduced ejection fraction gets the four standard medications for heart failure with reduced ejection fraction. Sacubitril-valsartan (Entresto), or an ACE inhibitor or an ARB (angiotensin receptor blocker) if Entresto isn’t tolerated, protects the heart from chronic strain. A beta-blocker such as carvedilol, metoprolol succinate, or bisoprolol slows the rate and improves survival. A mineralocorticoid receptor antagonist, spironolactone or eplerenone, blocks aldosterone, the hormone driving fluid retention and scarring. An SGLT2 inhibitor, dapagliflozin or empagliflozin, cuts heart failure events and slows kidney disease even without diabetes. Each works through a different pathway and the benefits stack, so a patient on all four lives longer, gets hospitalized less, and feels better than a patient on one or two. These drugs treat consequences, not the inflammation, which is why they’re layer three and the steroids are layer one.

What to expect long-term

Most patients stabilize for years on the right combination of immunosuppression, device therapy, and heart failure medication. Some have a single episode that responds to a year of treatment and never returns. Others relapse and need ongoing maintenance, often 5 to 10 milligrams of prednisone plus a steroid-sparing drug. A smaller group progresses despite everything and may eventually need a heart transplant.

Some damage reverses. Inflammation caught before it scars can resolve completely on the PET scan, heart block still in its inflammatory phase sometimes recovers enough that a pacemaker becomes unnecessary, and pumping can improve. Established scar does not, which is the whole argument for catching this early.

Surveillance means clinic visits every 3 to 6 months when you’re stable and more often during a taper, an echocardiogram every 6 to 12 months, a cardiac MRI every 1 to 2 years to track scar burden, a PET scan whenever we need to know whether inflammation is quiet, an EKG at every visit, and bloodwork for liver and kidney function, blood counts, blood sugar, and vitamin D, with bone density studies on chronic steroids.

We’re winning when the PET shows no active inflammation, the ejection fraction holds or improves, no new conduction problems appear, there are no ICD shocks or heart failure admissions, and you feel better than you did at diagnosis. We escalate when the PET lights up again, the ejection fraction drops, new arrhythmias or shocks appear, you’re admitted for heart failure, sarcoidosis turns up in another organ, or side effects get worse. Escalating means restarting higher-dose prednisone, adding a steroid-sparing agent, or referral to advanced heart failure for transplant evaluation.

Outlook depends heavily on how early the diagnosis was made. Isolated heart block with normal pumping and minimal scar on MRI usually runs a long stable course. Badly reduced pumping, extensive scar, or recurrent ventricular arrhythmias make for a tougher trajectory. Five-year survival across published series runs 60 to 90 percent depending on how those patients presented.

When to look for it

These are the patterns that should trigger a workup. An adult under 60 with new complete or advanced second-degree heart block and no clear coronary, valvular, or medication cause. Sustained ventricular tachycardia in someone whose heart looks fairly normal on the first echo, especially when the VT comes from the upper septum. New heart failure of unclear cause, especially with a thinned upper septum or a patchy scar that doesn’t match a coronary territory. Known sarcoidosis elsewhere in someone who develops palpitations, syncope, new EKG abnormalities, or unexplained fatigue. A family history of sarcoidosis with unexplained cardiac symptoms. In Black/African American and Scandinavian patients I lower the threshold further.

When to call me, and when to call 911

Call 911 immediately for chest pain that’s severe or doesn’t ease within a few minutes, severe shortness of breath at rest, fainting or near-fainting, sustained palpitations lasting more than a few minutes, or an ICD shock. Don’t drive yourself. Don’t wait it out.

Call my office the same day for new palpitations that come and go, lightheadedness that’s new for you, worsening exercise tolerance, new swelling in the legs or ankles, or any concern that’s gnawing at you. Same-day contact catches problems while they’re still easy to fix.

Schedule a clinic visit within a week or two for questions about medications, bothersome side effects that aren’t dangerous, questions about diet, exercise, travel, or work, or anything you want to talk through.

Questions I get

Can I exercise? In most cases yes. Stable disease, normal or near-normal pumping, and no significant arrhythmia history usually means moderate aerobic exercise is fine. Active inflammation, recent VT, or badly reduced pumping calls for a more conservative approach. Cardiac rehabilitation is a good structured setting for getting back to it, and the limits come from your cardiologist, not a blanket rule.

Is sarcoidosis hereditary? There’s a familial component, with first-degree relatives at slightly higher risk. The genetics are complex and no single gene predicts it, and there’s no established screening recommendation for symptom-free relatives. A relative with chronic cough, unexplained breathlessness, eye inflammation, skin lesions, palpitations, or syncope should be evaluated like anyone else with those symptoms, with the family history factored in.

How is this different from other diseases that infiltrate the heart? Cardiac amyloidosis, where a misfolded protein deposits in the muscle, comes in ATTR and AL types with different treatments now available. Hemochromatosis is iron overload from a genetic disease or repeated transfusions. Anderson-Fabry disease is a rare genetic condition where one enzyme is missing. Each has a distinct pattern on cardiac MRI, distinct blood tests, and distinct treatment, and MRI with late gadolinium enhancement is what sorts among them most reliably.

Can I have a baby? In many cases yes, and pregnancy with cardiac sarcoidosis is high risk and needs planning with a maternal-fetal medicine specialist alongside your cardiologist. Methotrexate, mycophenolate, ACE inhibitors, and ARBs such as valsartan are contraindicated in pregnancy and have to be stopped or swapped well before conception. Prednisone is generally considered safe at reasonable doses. Get pumping function and arrhythmia risk optimized first, and talk to your cardiologist several months before you start trying.

If someone you know has new heart block, unexplained palpitations or syncope, or a heart failure picture that doesn’t add up, raise cardiac sarcoidosis explicitly. The workup is straightforward once it’s on the radar. The patients I worry about are the ones whose pacemaker went in without anyone asking.

References

1. Birnie, David H., et al. “HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated with Cardiac Sarcoidosis.” Heart Rhythm 11, no. 7 (2014): 1305-1323.

2. Crouser, Elliott D., et al. “Diagnosis and Detection of Sarcoidosis: An Official American Thoracic Society Clinical Practice Guideline.” American Journal of Respiratory and Critical Care Medicine 201, no. 8 (2020): e26-e51.

3. Chen, Eugene S., and David R. Moller. “Cardiac Sarcoidosis.” Clinics in Chest Medicine 36, no. 4 (2015): 657-668.

4. Yazaki, Yoshikazu, et al. “Comparison of Clinical Features and Prognosis of Cardiac Sarcoidosis and Idiopathic Dilated Cardiomyopathy.” American Journal of Cardiology 88, no. 9 (2001): 1006-1010.

5. Kandolin, Riina, et al. “Cardiac Sarcoidosis: Epidemiology, Characteristics, and Outcome over 25 Years in a Nationwide Study.” Circulation 131, no. 7 (2015): 624-632.

6. Sadek, Mouhannad M., et al. “Corticosteroid Therapy for Cardiac Sarcoidosis: A Systematic Review.” Canadian Journal of Cardiology 29, no. 9 (2013): 1034-1041.

7. Blankstein, Ron, et al. “Cardiac Positron Emission Tomography Enhances Prognostic Assessments of Patients with Suspected Cardiac Sarcoidosis.” Journal of the American College of Cardiology 63, no. 4 (2014): 329-336.

8. Hulten, Edward, et al. “Cardiac Sarcoidosis: State of the Art Review.” Cardiovascular Diagnosis and Therapy 6, no. 1 (2016): 50-63.

9. Greulich, Simon, et al. “CMR Imaging Predicts Death and Other Adverse Events in Suspected Cardiac Sarcoidosis.” JACC: Cardiovascular Imaging 6, no. 4 (2013): 501-511.

10. Ribeiro Neto, Manuel L., et al. “Heart Transplantation in Patients with Cardiac Sarcoidosis.” Journal of Heart and Lung Transplantation 41, no. 6 (2022): 727-734.

11. Skali, Hicham, Allison R. Schulman, and Sharmila Dorbala. “18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis.” Current Cardiology Reports 15, no. 4 (2013): 352.

12. Kron, Jordana, et al. “Efficacy and Safety of Implantable Cardiac Defibrillators for Treatment of Ventricular Arrhythmias in Patients with Cardiac Sarcoidosis.” Europace 15, no. 3 (2013): 347-354.